WPD Pharmaceuticals’ Annamycin Received Positive Interim Results From Phase 1/2 Clinical Studies in Acute Myeloid Leukemia
VANCOUVER, British Columbia, Feb. 27, 2020 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “Company” or “WPD”), a clinical stage pharmaceutical company is pleased to provide an update on the clinical drug studies of Annamycin in …